ABUS

On the operating business alone, ABUS looks unownable: FY2025 revenue of $14.1M against a $866M market cap is a 61.5x P/S, the company burned $39.6M in operating cash, and management slashed headcount by 57% on top of the prior 40% cut, exited the Warminster HQ and 'discontinued in-house scientific research.' Net margin of -237.9% and just $18.0M cash on hand would normally signal a dilution-or-die setup. But the 10-K materially rewrites that picture: on March 3, 2026 Arbutus, Genevant and Moderna signed a settlement under which Moderna pays an aggregate $950.0M Noncontingent Settlement Payment 'on or before July 8, 2026,' with Arbutus entitled to '20% of the Noncontingent Settlement Payment' after litigation costs — roughly $190M direct — plus its disclosed ~16% stake in Genevant, which captures meaningful additional economics on Genevant's 80% share.

This is a near-certain, dated cash event roughly 5 weeks away versus a current enterprise value of about $848M. Management is explicit that it is 'currently evaluating a return of capital to our shareholders in the third quarter of calendar year 2026, following the receipt of our portion of the Noncontingent Settlement Payment,' which provides a direct shareholder transmission mechanism rather than a black-box re-investment risk. The balance sheet has zero long-term debt and only $6.01M current liabilities, so essentially all of the settlement flows to equity.